Million dollars. The cost of treating one patient diagnosed with a rare disease
A heavy price to heal hereditary disorder increases the risk of pancreatitis
 |
| rare,disease,Stem cells,Multiple Sclerosis,Ms,Health,Medicine,Disease,الخلايا الجذعيه,الصحه,الطب,الامراض,التصلب المتعدد |
Heralds
the first real estate West to fix damaged genes, new in the life of
patients with a rare disease causing blood clots, but the only stumbling
block is price.
And
is likely to cost the gene therapy of enzyme Lopes of lipoproteins, a
legacy of failure risk of pancreatitis may lead to death, more than $ 1
million per patient when markets in Europe this summer.
Rare
diseases and unprecedented attention from pharmaceutical companies, and
especially more than a quarter of new medicines approved in the United
States last year for such cases.
Since only a very small number of patients who need treatment, the total cost for a relatively limited health budgets.
But
providers of health care services has become increasingly must balance
the need for a limited number of patients and the broader interests of
the Community budget constrained.
There is a growing trend to reconsider these markups for this wave of medicines.
Carl
commented Claxton, Professor of health economics at York University,
that more companies within this sector, because it felt very high prices
that could be imposed on some of the medication these rare diseases.
He
added that "this situation cannot continue, health care systems around
the world in growing financial pressure, all of which began with very
carefully scrutinizes get for the money".
And
with more treatments, more scientists familiar with the reasons for
6,000 or 7,000 disease afflicts more than 1% of the population, there
are indications that those who pay for these drugs back down, especially
in Europe, experiencing severe retrenchment.
In the United States and Europe, rare diseases drugs changed ideas about what makes any pharmaceutical company profit.
Usually
pharmaceutical companies rely on drugs produced in large quantities to
treat ailments such as high cholesterol, but the patent periods allowed
competitors making cheaper copies, reducing profits in this area.
On the contrary, the rare diseases provides special rates, where rival companies.
While this policy has stimulated more innovation, that some investors feel nervous about future prices.
Analysis by Thomson Reuters that rare diseases drugs market worth more than 50 billion dollars at the end of 2011.
ليست هناك تعليقات:
إرسال تعليق